Metir Plc · LSE:MET
Metir — Microsaic Systems — FY2020 Earnings Presentation
15 slides from Metir's earnings presentation, 2021
Slide 1: Year End Results
Year End RESULTS www.microsaic.com
Slide 2: Important Information
IMPORTANT INFORMATION 2 This presentation, which has been prepared by Microsaic Systems plc ("Company"), has been prepared solely in connection with the Company’s results for the financial year ended 31 December 2020. For the purposes of this notice, "presentation" means this document, any oral pres
Slide 3: Introductions
INTRODUCTIONS 3 Glenn Tracey 20+ years’ experience in scientific instruments, in human and environmental health. Previously at global Chief Executive life sciences company PerkinElmer. Joined in March 2015, appointed CEO in 2018. 35+ years’ of financial management experience in Bevan Metcalf pharmac
Slide 4: 2020 Results
2020 RESULTS 4 COVID-19 severely impacted business during 2020 77.3% 70.5% 11.6% REVENUES GROSS PROFIT MARGINS Total revenue of £198k Gross profit in 2020 of GM 50.4% significantly reduced by 77.3% £99k (2019: £338k) fell higher (2019: 38.8%) due (2019: £872k) by 70.5% to a change in the product mix
Slide 5: 2021 Post Year-End
2021 Post Year-End 5 5 Feb 15 FEB 31 MAR Framework Quarter 1 £5.5m Agreement Revenue up 180% Fundraise Completion of over-subscribed 3-year agreement with initial order New Business Model has already placing and broker option with gross commitment of £100,000, delivered increase in revenues of proce
Slide 6: Strategic Focus: Market Verticals
STRATEGIC FOCUS 6 Point of Use HUMAN HEALTH DIVERSIFIED Lab-based analysis Portable, field-based screening Online monitoring Human Health Environmental Health Diversified Biologics PAT/ Bioprocessing and Remote water analysis Remote and in-field fuels analysis Market Verticals Point-of-Care Diagnost
Slide 7: Business Model Transformation
BUSINESS MODEL TRANSFORMATION 7 Revised 2021 business model – provide solutions for real-world problems Data analytics and digital infrastructure layer Software applications layer (scientific method + • Technology is an “enabler”, not just a “product sale” analysis) • We solve real world problems, a
Slide 8: Microsaic Agreement with DeepVerge
MICROSAIC AGREEMENT WITH DEEPVERGE 8 Non-exclusive agreement AI development integration Distribution of Microsaic products and services DeepVerge will immediately provide access to across the geographic markets addressed by its artificial intelligence platform to enhance DeepVerge revenues from exis
Slide 9: Our Immediate Strategy
OUR IMMEDIATE STRATEGY 9 1 / Transform Business Model 2 / Collaborations and Revenue Sharing Transform to annuity data-centric business model, Collaborate, cooperate and partner with increasing proportion of revenues from AI and Internet of complementary and support and service companies in Things (
Slide 10: China - Heads of Terms
CHINA - HEADS OF TERMS1 10 Patient-Centric Diagnostics Chinese Medical Device Partner: Distribution for hospital diagnostics Chinese Production 2021: Anticipating medical device license by 2022 Opportunity: 33,000 hospitals 7.9 million hospital beds 1) As announced, the Head of Terms with the Chines
Slide 11: Profit & Loss
PROFIT & LOSS 11 £000 2020 2019 2020: Revenue 198 872 • Revenues severely disrupted by COVID-19 Cost of sales (98) (534) • Gross margin 50% vs 39% due to product mix • Other operating income - Furlough grant Gross profit 100 338 • Contingency plan – savings in payroll related, Other operating income
Slide 12: Balance Sheet
BALANCE SHEET 12 2020: • Right of use assets – terminated a lease early £000 2020 2019 • Inventories up £0.2m, reflecting lower unit sales ASSETS Intangible assets 84 97 • R&D tax credit lower on reduced as expenditure Property, plant and equipment 114 125 • Receivables impacted by low sales volumes
Slide 13: Cash Flow
CASH FLOW 13 2020: £000 2020 2019 • Cash used in operating activities reduced by Cash used in operations (2,371) (2,842) £0.5m mainly due to the implementation of a Corporation tax received 321 277 contingency plan Net cash used in operating activities (2,050) (2,565) • Cash runway extended by staff
Slide 14: Year in Review - 2020: Experience and Outlook
YEAR IN REVIEW - 2020 14 Experience and Outlook While 2020 was a challenging year for the Company, the new year, with fresh funding injected and new Directors appointed to the Board, has already brought strategic changes which have identified multiple growth opportunities: • Shared sales, marketing
Slide 15: Annual Report
ANNUAL ? ? REPORT V? . : Savega Microsaic OSES “gfe systems